NASDAQ:BCEL Atreca Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Atreca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.23 +0.44 (+24.58%) (As of 07/5/2022 05:45 PM ET) Add Compare Share Today's Range$1.72▼$2.2750-Day Range$1.56▼$2.2152-Week Range$1.51▼$9.77Volume609,563 shsAverage Volume1.11 million shsMarket Capitalization$84.20 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Atreca MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside591.2% Upside$15.00 Price TargetShort InterestBearish14.25% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.31Based on 3 Articles This WeekInsider TradingSelling Shares$30,300 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.74) to ($2.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.34 out of 5 starsMedical Sector177th out of 1,428 stocksPharmaceutical Preparations Industry74th out of 680 stocks 3.5 Analyst's Opinion Consensus RatingAtreca has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Atreca has a forecasted upside of 591.2% from its current price of $2.17.Amount of Analyst CoverageAtreca has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.25% of the float of Atreca has been sold short.Short Interest Ratio / Days to CoverAtreca has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Atreca has recently decreased by 0.25%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAtreca does not currently pay a dividend.Dividend GrowthAtreca does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAtreca has received a 72.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Atreca is -0.85. Previous Next 2.4 News and Social Media Coverage News SentimentAtreca has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Atreca this week, compared to 1 article on an average week.Search Interest12 people have searched for BCEL on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Atreca to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atreca insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,300.00 in company stock.Percentage Held by InsidersOnly 9.60% of the stock of Atreca is held by insiders.Percentage Held by Institutions57.48% of the stock of Atreca is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Atreca are expected to grow in the coming year, from ($2.74) to ($2.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atreca is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atreca is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtreca has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter. Email Address About Atreca (NASDAQ:BCEL) StockAtreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.Read More BCEL Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comAtreca, Inc. (NASDAQ:BCEL) Insider Tito Serafini Sells 15,000 Shares of StockJune 27, 2022 | streetinsider.comCellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer - StreetInsider.comJune 16, 2022 | globenewswire.comAtreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer - GlobeNewswireJune 16, 2022 | finance.yahoo.comAtreca Appoints Stephen Gould, Ph.D. as Chief Scientific OfficerJune 7, 2022 | globenewswire.comUrothelial Carcinoma Pipeline Insights | Clinical Trials Evaluation Report 2022 | DelveInsight - GlobeNewswireJune 2, 2022 | globenewswire.comAtreca Announces Corporate Reorganization to Extend Cash Runway - GlobeNewswireJune 1, 2022 | finance.yahoo.comAtreca Announces Corporate Reorganization to Extend Cash RunwayMay 21, 2022 | finance.yahoo.comAtreca to Present at Upcoming Investor Conferences - Yahoo FinanceMay 20, 2022 | streetinsider.comAtreca to Present at Upcoming Investor Conferences - StreetInsider.comMay 19, 2022 | benzinga.comAtreca to Present at Upcoming Investor Conferences - Benzinga - BenzingaMay 19, 2022 | globenewswire.comAtreca to Present at Upcoming Investor Conferences - GlobeNewswireMay 19, 2022 | finance.yahoo.comAtreca to Present at Upcoming Investor ConferencesMay 13, 2022 | benzinga.comRecap: Atreca Q1 Earnings - Benzinga - BenzingaMay 13, 2022 | finance.yahoo.comAtreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments - Yahoo FinanceMay 11, 2022 | finance.yahoo.comAtreca Reports First Quarter 2022 Financial Results and Recent Corporate DevelopmentsMay 5, 2022 | streetinsider.comAtreca (BCEL) received a Notice of Allowance for its US patent application 16/792115 titled "ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND THERAPY" - Patent Grants - StreetInsider.comMay 4, 2022 | finance.yahoo.comZymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results - Yahoo FinanceMay 4, 2022 | globenewswire.comAtreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101” - GlobeNewswireMay 4, 2022 | finance.yahoo.comAtreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101”April 22, 2022 | seekingalpha.comAtreca: Biotech With Promise Based On First Candidate ATRC-101 - Seeking AlphaApril 8, 2022 | finance.yahoo.comNanoString Highlights Spatial Biology Research at the 2022 American Association of Cancer Research (AACR) Conference - Yahoo FinanceApril 6, 2022 | investing.comPre-Open Stock Movers 04/06: TUFN, BTAI, TLRY Higher; CANO, CAR, JBLU Lower By Investing.com - Investing.comApril 5, 2022 | finance.yahoo.comAtreca Announces Expansion of Preclinical Pipeline - Yahoo FinanceApril 5, 2022 | finance.yahoo.comEmerald Health Pharmaceuticals Strengthens Global Patent Portfolio with New International Patents - Yahoo FinanceApril 5, 2022 | globenewswire.comAtreca Announces Expansion of Preclinical Pipeline - GlobeNewswireSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCEL CUSIPN/A CIK1532346 Webwww.atreca.com Phone(650) 595-2595FaxN/AEmployees134Year FoundedN/ACompany Calendar Last Earnings5/11/2022Today7/05/2022Next Earnings (Estimated)8/10/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$25.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+572.6%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.05% Return on Assets-49.58% Debt Debt-to-Equity RatioN/A Current Ratio9.57 Quick Ratio9.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.10 per share Price / Book0.54Miscellaneous Outstanding Shares37,759,000Free Float34,134,000Market Cap$84.20 million OptionableNot Optionable Beta0.64 Atreca Frequently Asked Questions Should I buy or sell Atreca stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Atreca stock. View analyst ratings for Atreca or view top-rated stocks. What is Atreca's stock price forecast for 2022? 4 brokerages have issued 1-year target prices for Atreca's shares. Their BCEL stock forecasts range from $9.00 to $25.00. On average, they expect Atreca's share price to reach $15.00 in the next year. This suggests a possible upside of 572.6% from the stock's current price. View analysts' price targets for Atreca or view top-rated stocks among Wall Street analysts. How has Atreca's stock performed in 2022? Atreca's stock was trading at $3.03 at the start of the year. Since then, BCEL stock has decreased by 26.4% and is now trading at $2.23. View the best growth stocks for 2022 here. When is Atreca's next earnings date? Atreca is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for Atreca. How were Atreca's earnings last quarter? Atreca, Inc. (NASDAQ:BCEL) posted its earnings results on Wednesday, May, 11th. The company reported ($0.65) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.13. View Atreca's earnings history. Who are Atreca's key executives? Atreca's management team includes the following people: Mr. John A. Orwin, Pres, CEO & Director (Age 57, Pay $889.51k)Dr. Tito A. Serafini Ph.D., Founder, Chief Strategy Officer & Director (Age 59, Pay $662.77k)Mr. Herbert C. Cross, Chief Financial Officer (Age 50, Pay $589.23k)Dr. Yann Chong Tan, Chief TechnologistMs. Courtney J. Phillips J.D., Gen. Counsel & Corp. Sec. (Age 47)Dr. Daniel Emerling, Sr. VP of ResearchDr. Jonathan Benjamin M.D., Ph.D., Sr. VP of Clinical Research What is John Orwin's approval rating as Atreca's CEO? 2 employees have rated Atreca CEO John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among Atreca's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Atreca's key competitors? Some companies that are related to Atreca include Precigen (PGEN), Ocular Therapeutix (OCUL), PyroGenesis Canada (PYR), Biomea Fusion (BMEA), DiaMedica Therapeutics (DMCAF), Silence Therapeutics (SLN), OptiNose (OPTN), Heron Therapeutics (HRTX), OrganiGram (OGI), Pliant Therapeutics (PLRX), AC Immune (ACIU), Biotech Acquisition (BIOT), CytoDyn (CYDY), Aadi Bioscience (AADI) and Alpine Immune Sciences (ALPN). View all of BCEL's competitors. What other stocks do shareholders of Atreca own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atreca investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Homology Medicines (FIXX), Akero Therapeutics (AKRO), Hookipa Pharma (HOOK), Lumentum (LITE), TCR2 Therapeutics (TCRR) and Precision BioSciences (DTIL). When did Atreca IPO? (BCEL) raised $126 million in an initial public offering on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers. What is Atreca's stock symbol? Atreca trades on the NASDAQ under the ticker symbol "BCEL." How do I buy shares of Atreca? Shares of BCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Atreca's stock price today? One share of BCEL stock can currently be purchased for approximately $2.23. How much money does Atreca make? Atreca (NASDAQ:BCEL) has a market capitalization of $84.20 million. The company earns $-109,320,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. How many employees does Atreca have? Atreca employs 134 workers across the globe. How can I contact Atreca? Atreca's mailing address is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. The official website for Atreca is www.atreca.com. The company can be reached via phone at (650) 595-2595 or via email at ir@atreca.com. This page (NASDAQ:BCEL) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
